Evidence map›Paper›PMID 36070022›Full record

ArticleCell biology and toxicology2023

Berbamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells.

Yujuan Zhan, Qiugu Chen, Yue Song, Xianli Wei, Tingxiu Zhao, Bonan Chen, Chengxi Li, Wenbo Zhang, Yanjun Jiang, Yuhui Tan and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biology and toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. HIV-1 gp120-induced lysosomal stress responses are controlled by TRPML1 redox sensors.Redox report : communications in free radical research · 2026
    Article
  3. Tetrahydrocurcumin Attenuates NaIOAntioxidants (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yujuan Zhan *Department of Biochemistry, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Qiugu Chen *Department of Biochemistry, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Yue Song *Department of Biochemistry, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Xianli WeiDepartment of Medical Instruments, Guangdong Food and Drug Vocational College, Guangzhou, 510520, People's Republic of China.
Tingxiu ZhaoDepartment of Pathology, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Bonan ChenDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, SAR 999077, China.
Chengxi LiResearch Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Wenbo ZhangResearch Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Yanjun JiangDepartment of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, SAR 999077, China.
Yuhui TanDepartment of Biochemistry, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Biaoyan DuDepartment of Pathology, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Jianyong XiaoDepartment of Biochemistry, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. jianyongxiao@gzucm.edu.cn.
Kun WangDepartment of Pathology, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. wangkun@gzucm.edu.cn.
Guangzhou University of Chinese Medicine · CNChinese University of Hong Kong · CNGuangdong Food and Drug Vocational College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autophagy is typically activated in cancer cells as a rescue strategy in response to cellular stress (e.g., chemotherapy). Herein, we found that Berbamine Hydrochloride (Ber) can act as an effective inhibitor of the late stage of autophagic flux, thereby potentiating the killing effect of chemotherapy agents. Lung carcinoma cells exposed to Ber exhibited increased autophagosomes, marked by LC3-II upregulation. The increased level of p62 after Ber treatment indicated that the autophagic flux was blocked at the late stage. The lysosome staining assay and cathepsin maturation detection indicated impaired lysosomal acidification. We found that Nox2 exhibited intensified co-localization with lysosomes in Ber-treated cells. Nox2 is a key enzyme for superoxide anion production capable of transferring electrons into the lysosomal lumen, thereby neutralizing the inner protons; this might explain the aberrant acidification. This hypothesis is further supported by the observed reversal of lysosomal cathepsin maturation by Nox2 inhibitors. Finally, Ber combined with cisplatin exhibited a synergistic killing effect on lung carcinoma cells. Further data suggested that lung carcinoma cells co-treated with Ber and cisplatin accumulated excessive reactive oxygen species (ROS), which typically activated MAPK-mediated mitochondria-dependent apoptosis. The enhanced anti-cancer effect of Ber combined with cisplatin was also confirmed in an in vivo xenograft mouse model. These findings indicate that Ber might be a promising adjuvant for enhancing the cancer cell killing effect of chemotherapy via the inhibition of autophagy. In this process, Nox2 might be a significant mediator of Ber-induced aberrant lysosomal acidification.

Indexed as

Antineoplastic AgentsCarcinomaLung NeoplasmsAnimalsApoptosisAutophagyBenzylisoquinolinesCathepsinsCisplatinHumansHydrogen-Ion ConcentrationLungLysosomesMiceReactive Oxygen SpeciesAntineoplastic AgentsBenzylisoquinolinesberbamineCathepsinsCisplatinReactive Oxygen SpeciesApoptosisAutophagy inhibitionBerbamine HydrochlorideChemotherapy synergismROS

Identifiers

PMID36070022
OpenAlexW4294917669

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.